Acute Kidney Injury in Care Transitions (ACT) Trial

Overview

About this study

The purpose of this study is to evaluate the feasibility and acceptability of the AKI in Care Transitions pilot and iteratively refine the intervention.  Generate preliminary estimates of the ACT intervention on clinical and patient-reported outcomes.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria - Clinician:

  • All clinicians responsible for caring for eligible patients will be considered for inclusion in the qualitative research. 

Exclusion Criteria - Clinician:

  • If the clinician declines to participate, the patient is still eligible for the study, but qualitative evaluations will be omitted.

Inclusion Criteria - Patient:

  • Participants will be recruited from those identified by a developed electronic health record list of patients with AKI. 
  • Included individuals that populate the list are those with stage III AKI (severe) during a hospitalization based on serum creatinine rise or urine output decline from Olmsted County.

Exclusion Criteria - Patient: 

  • Dementia.
  • Non-English speaking.
  • Expected to be dismissed to a skilled nursing facility or hospice at discharge.
  • Expected to need dialysis at discharge.
  • Primary Care Transitions Program enrollment.
  • Transplant recipients within 100 days of transplant.
  • Can only have one time enrollment.  

Eligibility last updated 1/18/22. Questions regarding updates should be directed to the study team contact.

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Erin Barreto, Pharm.D., R.Ph.

Open for enrollment

Contact information:

Erin Barreto Pharm.D., R.Ph.

(507) 255-5732

Barreto.Erin@mayo.edu

More information

Publications

Publications are currently not available
.
CLS-20526652

Mayo Clinic Footer